<DOC>
	<DOCNO>NCT00385437</DOCNO>
	<brief_summary>This concurrent , two-part study : I ) Using overnight sleep recording , evaluate short- long-term sleep-promoting effect antidepressant mirtazapine ( Remeron ) patient prescribe medication major depressive disorder sleep disruption . II ) Investigate psychomotor performance depress patient use drive simulation test treatment mitrazapine .</brief_summary>
	<brief_title>Sedating Antidepressant Improves Driving Safety Patients With Major Depressive Disorder</brief_title>
	<detailed_description>In treatment depression , role sleep important mutual relationship mood disorder sleep disorder . Over 80 % major depressive disorder ( MDD ) patient report sleep problem . Depression strongly impair cognitive functioning daytime alertness . ( Mirtazapine ( Remeron ) antidepressant sleep-promoting agent available Canada year . However , research investigate effect mirtazapine sleep limited know short- long-term change sleep architecture associate drug daytime performance affect . Rationale : The co-existence depression sleep difficulty common . Mirtazapine market single modality treatment depression impair sleep . As sleep clinic psychiatry department , single modality treatment depressive sleep disorder prefer patient help improve compliance treatment . However , 7 publish study investigate effect mirtazapine sleep significant limitation . None study objectively examine mirtazapine â€™ short- long-term sleep architecture daytime function ( daytime sleepiness , alertness , drive performance ) depress patient . This study address issue . Hypothesis : I ) Mirtazapine produce immediate long- improvement effect sleep patient major depressive disorder . There may impairments alertness first two day start treatment daytime alertness recover one week . II ) Patients treat mitrazapine show rapid , initial improvement drive performance recovery sleep slower , improvement treatment depression translate well sleep quality well improvement attention , alertness concentration . Study Design : This pilot proposal two-part longitudinal , open-label clinical study consecutive enrollment subject . This research study take place conjunction normal clinical practice . Patients depression sleep disorder commonly see sleep clinic mirtazapine one several antidepressant prescribe clinician . In study , follow group patient prescribe mirtazapine one clinic physician meet inclusion exclusion list . There additional number sleep study ( 10 total versus usual 2 3 ) perform ; usual daytime test conduct part standard care ( Multiple Sleep Latency Test ( MSLT ) Maintenance Wakefulness Test ( MWT ) ) ; administer additional questionnaire assess subjective sleepiness , alertness fatigue ; , drive simulator test conduct accordance normal standard care .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Fulfilling DSMIV criterion Major Depressive Disorder Score Hamilton Rating Scale Depression ( HDRS17 ) &gt; 17 Patient prescribe mirtazapine ( Remeron ) determine physician Subject know clinically significant abnormal vital sign clinical finding screen . Patients drive license 3 year drive 15,000 km year . Females childbearing potential must willingly use effective birth control . Night shift worker . A history present condition : Bipolar Disorder Depressive Disorder Otherwise Specified , Schizophrenia psychotic disorder ( accord DSMIV ) , Schizotypal Borderline personality disorder , Organic mental disorder A present condition : Anxiety Disorders ( accord DSMIV ) , Eating Disorders , Postpartum Depression Epilepsy history seizure disorder ever receive treatment anticonvulsant medication epilepsy seizures PSG record extremely abnormal sleep EEG ( would expect depression ) Alcohol substance abuse ( accord DSMIV ) last 6months prior baseline . Any physical disease , may explain symptom depression . Any chronic physical disease , stabilize .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>Driving safety</keyword>
	<keyword>maintenance wakefulness test</keyword>
	<keyword>major depressive disorder</keyword>
	<keyword>mirtazapine</keyword>
</DOC>